Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

T1D Exchange

- PMLiVE

Novo Nordisk invests £115m in Oxford diabetes unit

But Danish pharma company admitted Brexit had made it a harder decision

- PMLiVE

Lilly pilots enhanced online trial information

Company aims to aid comprehension of the informed consent process

- PMLiVE

J&J pondering future of diabetes device assets

Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales

Eli Lilly HQ

Lilly to buy migraine drug developer CoLucid for $960m

Deal revolves around lasmiditan, which the firm out-licensed in 2005

Novo signs personalised digital health deal in diabetes

Will work with Glooko on jointly-developed and branded solutions

Eli Lilly HQ

Lilly streamlines and culls leadership roles

Merges Europe and emerging markets interests and expands diabetes and oncology

Eli Lilly HQ

Lilly taps AstraZeneca for another anti-amyloid drug

MEDI1814 could potentially slow the progression of Alzheimer's

- PMLiVE

New Jardiance label could boost sales by $1.7bn, says analyst

Diabetes treatment can reduce the risk of cardiovascular death in type 2 patients

- PMLiVE

EU citizens are living longer, but not always in good health

Report finds huge inequalities between and within countries despite higher life expectancy

- PMLiVE

Sanofi launches ‘Highs & Lows’ diabetes awareness campaign

Highlights impact of emotional and psychological factors on effective self-management

Sanofi reception

FDA clears rival diabetes combos from Sanofi and Novo Nordisk

Xultophy set to launch in first half of 2017 while Soliqua is intended for January roll-out

- PMLiVE

Gilead’s hepatitis B virus treatment set for European approval

CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links